ArticleJournal of diabetes and metabolic disorders2026
Translation, cultural adaptation, and psychometric evaluation of the arabic version of the type 1 diabetes stigma assessment scale (DSAS-1-Ar) among adults in Jazan, Saudi Arabia.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes-related stigma adversely affects psychological wellbeing, self-care behaviors, and glycemic control in individuals with Type 1 diabetes (T1D). Despite the high prevalence of T1D in the Middle East and North Africa region, validated Arabic instruments to assess stigma remain limited. This study aimed to translate, culturally adapt, and evaluate the psychometric properties of the Arabic version of the Type 1 Diabetes Stigma Assessment Scale (DSAS-1-Ar) from the original English instrument. Methods: A cross-sectional study was conducted among 299 adults with T1D attending the Endocrinology and Diabetes Centre in Jazan, Saudi Arabia, recruited using consecutive sampling (response rate 99.3%). Translation followed established cross-cultural adaptation guidelines. Construct validity was examined using confirmatory factor analysis, with three competing structural models tested. In addition, Known-groups comparisons were executed between DSAS-1-Ar scores and self-reported clinical variables. Results: All 19 items loaded significantly onto their hypothesized latent factors (Treated Differently (TD), Blame and Judgment (BJ), and Identity Concerns (IC); standardised loadings 0.642-0.947). Internal consistency was good (total α = 0.985, ω = 0.986). None of the three compared structural models met conventional fit thresholds (CFI range 0.812-0.888; RMSEA range 0.167-0.202). SRMR for the three-factor model was acceptable (0.065), while CFI (0.816) and RMSEA (0.202) indicated suboptimal global fit. Known-groups validation analyses yielded plausibly different scores across distinct populations; e.g. higher stigma scores among females, older participants and those with diabetes-related complications. Conclusions: The DSAS-1-Ar represents an important initial step toward assessing T1D-related stigma in Arabic-speaking populations. Items loaded strongly onto theoretically assigned subscales and internal consistency was good. However, global CFA fit indices were suboptimal, indicating that the factor structure requires further evaluation in this cultural context. Future studies can include assessing convergent validity, test-retest stability, and model fit in more diverse Arabic-speaking samples. Trial registration: Clinical trial number: not applicable. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-026-02022-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.